

James Larkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/272595/publications.pdf>

Version: 2024-02-01

168
papers

64,134
citations

21215

62
h-index

9605

147
g-index

172
all docs

172
docs citations

172
times ranked

55262
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
2	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
3	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892.	13.9	6,769
4	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	13.9	4,838
5	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
6	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
7	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	5.1	2,353
8	Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	13.9	1,824
9	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
10	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
11	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009.	18.1	1,727
12	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
13	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
14	Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
15	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	6.3	1,175
16	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014, 46, 225-233.	9.4	1,103
17	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	5.1	1,089
18	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	6.3	1,032

#	ARTICLE	IF	CITATIONS
19	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	0.8	930
20	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
21	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260.	5.1	832
22	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482.	5.1	762
23	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021.	5.1	716
24	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018, 173, 581-594.e12.	13.5	609
25	Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β 1/FAK Signaling. <i>Cancer Cell</i> , 2015, 27, 574-588.	7.7	485
26	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	13.5	485
27	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	0.8	458
28	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
29	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
30	Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266.	3.2	424
31	Immune checkpoint inhibitors and cardiovascular toxicity. <i>Lancet Oncology</i> , The, 2018, 19, e447-e458.	5.1	376
32	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
33	Adjuvant nivolumab versus ipilimumab in resected stage IIIâ€™C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	5.1	330
34	Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256.	7.7	299
35	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
36	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256

#	ARTICLE	IF	CITATIONS
37	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology, The</i> , 2014, 15, 436-444.	5.1	242
38	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	1.3	236
39	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600 Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
40	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 643-654.	5.1	224
41	Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma. <i>JAMA Oncology</i> , 2015, 1, 433.	3.4	201
42	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.	2.0	201
43	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
44	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019, 20, e378-e389.	5.1	155
45	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
46	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	0.8	145
47	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948.	0.9	141
48	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
49	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131
50	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
51	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
52	Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology, The</i> , 2016, 17, e4-e5.	5.1	103
53	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336.	5.8	100
54	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84

#	ARTICLE	IF	CITATIONS
55	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	0.8	83
56	5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235.	3.2	82
57	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	3.0	81
58	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075.	0.8	78
59	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018, 74, 611-620.	0.9	77
60	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
61	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	1.3	71
62	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
63	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
64	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600 Mutated Metastatic Melanoma. <i>JAMA Oncology</i> , 2018, 4, 1382.	3.4	65
65	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
66	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69.	1.3	63
67	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800.	5.8	61
68	Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. <i>Human Molecular Genetics</i> , 2013, 22, 825-831.	1.4	54
69	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791.	1.3	53
70	Epigenetic regulation in RCC: opportunities for therapeutic intervention?. <i>Nature Reviews Urology</i> , 2012, 9, 147-155.	1.9	51
71	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	2.9	51
72	SnapShot: Renal Cell Carcinoma. <i>Cell</i> , 2015, 163, 1556-1556.e1.	13.5	50

#	ARTICLE	IF	CITATIONS
73	Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 92-100.	1.5	44
74	An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 561-570.	1.0	43
75	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	0.8	43
76	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021, 10, 327.	1.8	37
77	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 655-664.	5.1	37
78	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. <i>Journal of Clinical Oncology</i> , 2022, 40, 9522-9522.	0.8	37
79	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	1.4	35
80	Efficacy of PD-1 based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019, 116, 207-215.	1.3	35
81	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	1.3	33
82	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	3.7	33
83	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	0.8	33
84	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	0.8	33
85	Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. <i>Clinical Cancer Research</i> , 2017, 23, 5238-5245.	3.2	32
86	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF ^{V600} -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246.	3.2	32
87	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020, 26, 4201-4205.	3.2	30
88	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102.	3.4	30
89	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	1.8	29
90	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). <i>Cancer Research</i> , 2021, 81, CT004-CT004.	0.4	28

#	ARTICLE	IF	CITATIONS
91	Axitinib for the Treatment of Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 397-403.	0.6	23
92	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 167.e17-167.e23.	0.8	22
93	Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. European Urology, 2017, 71, 845-847.	0.9	22
94	PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. European Journal of Cancer, 2015, 51, 359-366.	1.3	21
95	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncology, 2020, 16, 2165-2175.	1.1	20
96	Common Variation at 1q24.1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer. PLoS ONE, 2015, 10, e0122589.	1.1	19
97	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. European Journal of Cancer, 2021, 158, 156-168.	1.3	19
98	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group Study. European Journal of Cancer, 2017, 80, 55-62.	1.3	18
99	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open, 2020, 5, e000852.	2.0	18
100	Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2022, 165, 97-112.	1.3	18
101	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 2019, 19, 1102.	1.1	17
102	Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. , 2021, 9, e002742.		16
103	Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy, 2011, 11, 639-649.	1.1	14
104	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. Expert Review of Anticancer Therapy, 2017, 17, 647-655.	1.1	14
105	BMI and outcomes in melanoma: more evidence for the obesity paradox. Lancet Oncology, The, 2018, 19, 269-270.	5.1	14
106	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021, 31, 181-185.	0.6	14
107	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14
108	Is advanced renal cell carcinoma becoming a chronic disease?. Lancet, The, 2010, 376, 574-575.	6.3	11

#	ARTICLE	IF	CITATIONS
109	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	5.1	10
110	Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.	2.9	10
111	Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9505-9505.	0.8	10
112	Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e239-e247.	1.8	9
113	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. <i>Translational Oncology</i> , 2017, 10, 679-685.	1.7	9
114	Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. <i>Anticancer Research</i> , 2012, 32, 2399-406.	0.5	9
115	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1772-1782.	0.8	9
116	Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. <i>Human Molecular Genetics</i> , 2022, 31, 3001-3011.	1.4	9
117	CActUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9587-TPS9587.	0.8	8
118	The safety of nivolumab for the treatment of metastatic melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 955-961.	1.0	7
119	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877742.	1.4	7
120	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 17-25.	1.1	7
121	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6
122	Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. <i>Frontiers in Oncology</i> , 2015, 5, 195.	1.3	5
123	Carbonic anhydrase IX in resected clear cell RCC. <i>Nature Reviews Urology</i> , 2015, 12, 309-310.	1.9	5
124	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020, 6, 999-1005.	1.6	5
125	Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9574-9574.	0.8	5
126	Pembrolizumab in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 315-325.	0.1	4

#	ARTICLE	IF	CITATIONS
127	Pazopanib-Induced Alopecia, an Underestimated Toxicity?. <i>Frontiers in Oncology</i> , 2015, 5, 112.	1.3	4
128	Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-18.	1.5	4
129	Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9569-9569.	0.8	4
130	Systemic anti-cancer therapy (SACT) dataset. <i>Lancet Oncology</i> , The, 2014, 15, 1063.	5.1	3
131	Relapse models for clear cell renal carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e376-e378.	5.1	3
132	The combination of vemurafenib and cobimetinib in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1105-1111.	0.5	3
133	Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1-12.	1.3	3
134	Elevated Levels of <i>BRAF</i> ^{V600} Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-17.	1.5	3
135	Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2021, 62, 403-406.	0.4	3
136	CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4503-LBA4503.	0.8	3
137	Individualising treatment choices in a crowded treatment algorithm. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 160-168.	2.2	2
138	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. <i>Melanoma Management</i> , 2017, 4, 151-155.	0.1	2
139	PTU-009...Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. , 2018, , .		2
140	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
141	Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. <i>Lancet Oncology</i> , The, 2021, 22, 905-907.	5.1	2
142	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481.	0.8	2
143	Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. <i>European Journal of Cancer</i> , 2021, 156, 187-189.	1.3	2
144	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. , 2015, , .		2

#	ARTICLE	IF	CITATIONS
145	A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, TPS9597-TPS9597.	0.8	2
146	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. Melanoma Management, 2014, 1, 7-10.	0.1	1
147	Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". British Journal of Cancer, 2017, 116, e15-e15.	2.9	1
148	PWE-025...Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis. , 2018, , .		1
149	Reply to E. Hindi and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	0.8	1
150	Reply to E. Hindi. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
151	Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas. , 2012, , .		1
152	Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.. , 2013, , .		1
153	Abstract 4603: Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs.. Cancer Research, 2013, 73, 4603-4603.	0.4	1
154	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.. Journal of Clinical Oncology, 2022, 40, 306-306.	0.8	1
155	Advances in the Management of Metastatic Renal Cell Cancer. European Urology Supplements, 2009, 8, 758-761.	0.1	0
156	Advances in immunotherapy for melanoma. Melanoma Management, 2014, 1, 19-24.	0.1	0
157	Recent developments in melanoma management. Trends in Urology & Men's Health, 2016, 7, 8-12.	0.2	0
158	PNFLBA-16 FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY. Journal of Urology, 2017, 197, .	0.2	0
159	OP0165...EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY. , 2019, , .		0
160	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 343-354.	1.1	0
161	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2021, 39, 4547-4547.	0.8	0
162	Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.. Journal of Clinical Oncology, 2021, 39, 4579-4579.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.. , 2013, , .		0
164	Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel. , 2014, , .		0
165	Malignant melanoma (metastatic). Clinical Evidence, 2008, 2008, .	0.2	0
166	Reply to T. Olivier et al. Journal of Clinical Oncology, 2022, , JCO2200209.	0.8	0
167	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. Cancer Research, 2022, 82, A012-A012.	0.4	0
168	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. Cancer Research, 2022, 82, PR002-PR002.	0.4	0